Saatvik Green announces a new order win

The estimated CAPEX for the 3.6 GW Phase II cell facility is approximately Rs 1,700 Crores. The proposed funding is through a combination of debt and internal accruals, but the latest disclosure does not provide a quantified debt-to-equity ratio or rupee split. ^[1]

• CAPEX: About Rs 1,700 Crores for the 3.6 GW Phase II cell expansion. ^[1]
• Funding mix: Debt plus internal accruals, with no disclosed percentage allocation between the two sources. ^[1]
• Interpretation: Internal accruals are the equity-like component for project funding purposes, but a precise debt-to-equity ratio cannot be calculated without the company disclosing the respective amounts.

This should be distinguished from the broader Odisha manufacturing programme, for which earlier disclosures referred to total planned investment of around Rs 7,000 Crores across multiple phases, including ingot and wafer capacity. ^[2]

Phase I adds 4 GW of module manufacturing capacity at Gopalpur, alongside 2.4 GW of solar-cell capacity. The facility was reported ready for commissioning in the latest Q1 FY27 update. ^[3]

• Utilization: In FY26, Saatvik produced 3,162 MW at an effective capacity utilization of 84.07%, indicating that the existing manufacturing base was already operating at a high load before Phase I came on stream. ^[4]
• Order-book visibility: The confirmed order book stood at approximately 5.89 GW as of 31 March 2026, with the company describing this as medium-term business visibility. ^[4] A separate earnings-call summary indicated an execution window of around 18 months. ^[5]
• Capacity alignment: On a simple nameplate comparison, the 5.89 GW order book is larger than the 4 GW Phase-I module addition. This supports the rationale for expansion, but it should not be read as full pre-selling of the new plant: the reported backlog is not allocated by plant, technology or delivery schedule.
• Key caveat: The 84.07% utilization figure is for FY26, not a Q1 FY27 run rate. The latest Q1 FY27 update confirms commissioning readiness but does not provide a new utilization percentage or refreshed backlog quantum. ^[3]

Implication: The expansion appears demand-backed rather than aimed at filling a materially underutilized base. The principal execution variable is now commissioning and ramp-up timing: high historical utilization and a 5.89 GW backlog provide support, but the filings do not yet establish how quickly the full 4 GW line will be absorbed or how much of the order book will be serviced by Phase I.

Verdict: Saatvik’s 3.6 GW Phase II is a substantial integration step, but its disclosed timeline trails Vikram Solar’s. Saatvik is targeting Phase II commercial production by FY28, whereas Vikram is targeting 9 GW of cell capacity by December 2026 and a further 3 GW by FY28. ^{[6] [7] [8]}

Backward-integration tracker

The comparison is directional rather than perfectly like-for-like: Saatvik’s FY28 milestone refers to commercial production for Phase II, while Vikram’s December 2026 milestone refers to commissioning of its first 9 GW phase. Actual economic benefit will therefore depend on commissioning, qualification, utilisation and ramp-up, not just nameplate capacity.

Margin impact

Management’s stated direction is positive but not quantified at the gross-margin level. Coverage of Saatvik’s presentation reports that management expects a “significant increase in EBITDA and the bottom line” once cell manufacturing begins, as the company reduces dependence on imported cells and captures more value internally. ^[12]

However, the company has not provided a specific gross-margin target or uplift in percentage points. Accordingly, the supportable conclusion is:

• Near-term: Phase I commissioning and ramp-up should provide the first opportunity to reduce purchased-cell dependence.
• Medium-term: Phase II could deepen internal sourcing and improve value capture, with management expecting a material EBITDA and earnings benefit. ^[12]
• Uncertainty: The magnitude of gross-margin expansion remains undisclosed; it will depend on plant utilisation, manufacturing yields, domestic cell pricing and the cost burden of the new facilities. The 3.6 GW Phase II should therefore be treated as a future margin opportunity, not yet as a realised margin improvement.